Most Popular - This note was sent to PropThink’s Premium subscribers on Wednesday September 25. On August 22, Mr. King spotlighted a recently in-licensed asset at Oncothyreon (ONTY), … Continue Reading
Read NowLong Ideas - Last week, while most of PropThink’s research team was on vacation, Sunshine Heart (SSH) commenced a secondary offering that should net proceeds of approximately $37 … Continue Reading
Read NowLong Ideas - Shares of ViroPharma soared by 25% on Friday as Bloomberg reported that the drug developer has hired Goldman Sachs to explore takeover offers following interest … Continue Reading
Read NowLong Ideas - Targeted therapies are the oncologists’ precision tool in treating difficult cancers. Where early therapeutics like radiotherapy and chemotherapy tackle cancers by bombarding all rapidly dividing … Continue Reading
Read NowLong Ideas - ChemoCentryx (CCXI), which we originally recommended on August 5 as a play on upcoming Phase III data for the company’s lead drug candidate vercirnon, has … Continue Reading
Read NowLong Ideas - Last December, we called Orexigen (OREX) the obesity stock to own in 2013. Thus far, we’ve been spot on. Arena (ARNA) and Vivus (VVUS) have … Continue Reading
Read NowLong Ideas - BioLife Solutions, the Bothell, WA based supplier of biopreservation media products and contract manufacturer, has climbed over 100% since our April report on the company. … Continue Reading
Read Now